decor-left decor-right

News & Media

Gritstone Oncology is committed to providing the media with accurate and timely information.

2018 Archive

bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies
August 23, 2018

bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to those targets for use...

Gritstone Oncology Appoints Experienced Financial Executive, Steve E. Krognes, to its Board of Directors
August 9, 2018

Gritstone Oncology, Inc., an immuno-oncology company developing tumor-specific cancer immunotherapies to fight multiple cancer types, today announced the appointment of Steve E. Krognes to the company’s board of directors.

Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
July 19, 2018

Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001...

Gritstone Oncology Receives Notice of Allowance from U.S. Patent and Trademark Office on its Core Patent Application for Tumor Antigen Prediction Model
May 7, 2018

Gritstone Oncology, Inc., an immuno-oncology company developing personalized cancer immunotherapies to fight multiple cancer types, announced today that that it has received a Notice of Allowance...

Gritstone Oncology to Present First Data Bridging Tumor Antigen Identification and Potent Immunotherapy Delivery in Primates at 2018 AACR Annual Meeting
April 12, 2018

Gritstone Oncology, a personalized cancer immunotherapy company, today announced that preclinical data highlighting the company’s tumor-specific neoantigen (TSNA) identification platform, EDGE™ (Epitope Discovery in cancer GEnomes), and a novel, potent TSNA delivery approach will be presented during two poster presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting.

Gritstone Oncology Appoints Jayant Aphale, Ph.D. as Executive Vice President of Technical Operations
March 19, 2018

Gritstone Oncology, a personalized cancer immunotherapy company, today announced that preclinical data highlighting the company’s tumor-specific neoantigen (TSNA) identification platform, EDGE™ (Epitope Discovery in cancer GEnomes), and a novel, potent TSNA delivery approach will be...

Gritstone Oncology Appoints Jean-Marc Bellemin as Chief Financial Officer
January 23, 2018

Gritstone Oncology, a next-generation personalized cancer immunotherapy company, announced today the appointment of Jean-Marc Bellemin as Executive Vice President of Finance and Chief Financial Officer, effective January 5, 2018...

2017 Archive

Gritstone Oncology Opens New State-of-the-Art Personalized Cancer Immunotherapy Manufacturing Facility
November 28, 2017

Gritstone Oncology, a next-generation personalized cancer immunotherapy company, announced today the opening of a new 43,000 square-foot manufacturing facility in Pleasanton, CA.

Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients
October 18, 2017

Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Gritstone Oncology, a leader in personalized cancer immunotherapies, today announced a collaboration and license agreement.

FierceBiotech Names Gritstone Oncology as a “Fierce 15” Biotechnology Company of 2017
September 26, 2017

Gritstone Oncology, a next-generation personalized cancer immunotherapy company, has been named by FierceBiotech as one of 2017’s Fierce 15 biotechnology companies, recognizing it as one of the most promising private biotechnology companies in the industry.

Gritstone Oncology Secures $92.7 Million In Series B Financing
September 7, 2017

Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced the successful completion of a $92.7 million Series B preferred stock financing.

Gritstone Oncology Expands Scientific Advisory Board with Appointment of Immuno-Oncology Experts James L. Gulley and Alessandro Sette
June 1, 2017

Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of James L. Gulley, M.D., Ph.D., chief of the Genitourinary Malignancies Branch...

Gritstone Oncology Appoints Raphaël F. Rousseau, M.D., Ph.D., as Chief Medical Officer
May 3, 2017

Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced the appointment of Raphaël F. Rousseau, M.D., Ph.D., as chief medical officer. Dr. Rousseau, an experienced biotechnology drug developer in oncology and hematology..

First Public Data Presented from Gritstone Oncology’s Tumor Antigen Identification Platform for Personalized Cancer Immunotherapy
March 31, 2017

Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced the first reported data supporting its novel approach to tumor-specific neoantigen (TSNA) identification through integrated tumor tissue analysis and deep learning.

Gritstone Oncology to Present at Cowen and Company’s 37th Annual Health Care Conference
March 1, 2017

Gritstone Oncology, Inc. announced that Andrew Allen, M.D., Ph.D., the company’s president and chief executive officer, will present at Cowen and Company’s 37th Annual Health Care Conference in Boston, Mass., on Wednesday, March 8 at 9:30 a.m. Eastern Standard Time.  

2016 Archive

Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy
May 9, 2016

Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, and Gritstone Oncology, a private cancer immunotherapy company developing next-generation, personalized cancer therapeutics, today announced a clinical collaboration for development of novel, personalized immunotherapies combining both companies’ leading technologies. 

Top